Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials

Many patients with primary immunodeficiency (PID) require immunoglobulin G (IgG) replacement therapy, delivered as intravenous IgG (IVIG) or subcutaneous IgG (SCIG). We aim to identify trends in efficacy and safety that would not be evident in individual studies of small patient numbers. Seven open-...

Descripción completa

Detalles Bibliográficos
Autores principales: Jolles, Stephen, Rojavin, Mikhail A., Lawo, John-Philip, Nelson, Robert, Wasserman, Richard L., Borte, Michael, Tortorici, Michael A., Imai, Kohsuke, Kanegane, Hirokazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292970/
https://www.ncbi.nlm.nih.gov/pubmed/30415311
http://dx.doi.org/10.1007/s10875-018-0560-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292970/
https://www.ncbi.nlm.nih.gov/pubmed/30415311
http://dx.doi.org/10.1007/s10875-018-0560-5

Ejemplares similares